From another perspective, it is more noteworthy that the same substance may also induce dissimilar ferroptosis phenotypes in different target cells; for example, it was previously mentioned that propofol inhibits ferroptosis in cardiomyocytes by activating the Nrf2 pathway, whereas it enhances ferroptosis in tumour cells by modulating the p53/SLC7A11 pathway [39, 69]; this difference may be related to the triggering of different signalling pathways (Fig. 3). Here, TP53 is linked to neoplasm.